2019 American Academy of Dermatology (AAD) Annual Meeting

Share on: 
March 1 to March 5, 2019
Walter E Washington Convention Center
Washington, DC
United States

Research coauthored by RTI Health Solutions researchers will be presented at the upcoming AAD Meeting.

Comparative cost per time in response for tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. 

Patient preferences for treatment of moderate-to-severe psoriasis: a U.S. discrete-choice experiment survey. Feldman S, Poulos C, Gilloteau I, Mange B, Guana A, Boeri M, Germino B, Boehm K, Gutknecht M, Augustin M.

Cost-effectiveness of tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis.  Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A.

Please use the links below to reach out to RTI-HS researchers regarding this research.

Related Services:
Conference participants: